CASI Pharmaceuticals (CASI) Competitors $2.25 -0.13 (-5.46%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CASI vs. MIST, PMVP, CELU, IGMS, JMAC, MGX, ASRT, CABA, INMB, and STROShould you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Milestone Pharmaceuticals (MIST), PMV Pharmaceuticals (PMVP), Celularity (CELU), IGM Biosciences (IGMS), Maxpro Capital Acquisition (JMAC), Metagenomi (MGX), Assertio (ASRT), Cabaletta Bio (CABA), INmune Bio (INMB), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. CASI Pharmaceuticals vs. Its Competitors Milestone Pharmaceuticals PMV Pharmaceuticals Celularity IGM Biosciences Maxpro Capital Acquisition Metagenomi Assertio Cabaletta Bio INmune Bio Sutro Biopharma Milestone Pharmaceuticals (NASDAQ:MIST) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Do institutionals and insiders believe in MIST or CASI? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, MIST or CASI? CASI Pharmaceuticals has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M91.15-$41.52M-$0.84-2.03CASI Pharmaceuticals$28.54M0.97-$39.26M-$2.55-0.88 Does the media refer more to MIST or CASI? In the previous week, Milestone Pharmaceuticals had 9 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 11 mentions for Milestone Pharmaceuticals and 2 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.93 beat Milestone Pharmaceuticals' score of -0.06 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MIST or CASI? Milestone Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Is MIST or CASI more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. CASI Pharmaceuticals' return on equity of -972.55% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -1,672.29% -83.09% CASI Pharmaceuticals -129.05%-972.55%-77.33% Do analysts rate MIST or CASI? Milestone Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 310.56%. CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 77.78%. Given Milestone Pharmaceuticals' higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than CASI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCASI Pharmaceuticals beats Milestone Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CASI vs. The Competition Export to ExcelMetricCASI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.65M$2.49B$5.71B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-0.8821.7830.9125.28Price / Sales0.97545.41404.2188.50Price / CashN/A25.4525.2228.45Price / Book18.755.589.536.01Net Income-$39.26M$31.83M$3.26B$265.34M7 Day Performance30.06%5.23%4.66%2.89%1 Month Performance78.57%4.29%5.35%1.61%1 Year Performance-65.70%11.57%32.14%25.61% CASI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CASICASI Pharmaceuticals4.0712 of 5 stars$2.25-5.5%$4.00+77.8%-63.7%$27.65M$28.54M-0.88180Gap DownMISTMilestone Pharmaceuticals1.4435 of 5 stars$1.55+3.3%$7.00+351.6%+26.9%$80.20M$1M-1.9930Earnings ReportAnalyst RevisionPMVPPMV Pharmaceuticals3.036 of 5 stars$1.40-5.4%$5.50+292.9%-5.6%$78.43MN/A-0.8950CELUCelularity0.3221 of 5 stars$3.23-0.3%N/A+13.9%$77.60M$54.22M-1.22220News CoveragePositive NewsAnalyst ForecastIGMSIGM Biosciences4.5197 of 5 stars$1.29+1.6%$5.50+326.4%N/A$76.57M$2.68M-1.43190News CoverageAnalyst UpgradeJMACMaxpro Capital AcquisitionN/A$5.68+1.7%N/A+4,218.4%$76.20MN/A0.002,021Gap DownMGXMetagenomi2.5781 of 5 stars$1.83-4.7%$13.00+610.4%-34.0%$71.77M$52.29M-0.87236News CoverageEarnings ReportAnalyst ForecastASRTAssertio2.478 of 5 stars$0.73-0.5%$2.63+262.1%-29.3%$69.82M$124.96M-2.2720Earnings ReportCABACabaletta Bio2.8133 of 5 stars$1.33-2.2%$14.43+984.9%-62.3%$69.01MN/A-0.4950Positive NewsINMBINmune Bio1.9994 of 5 stars$2.40-6.3%$18.40+666.7%-64.5%$68.06M$10K-0.9710STROSutro Biopharma4.268 of 5 stars$0.77-3.7%$6.11+691.4%-79.1%$68.02M$62.04M-0.31240Gap Down Related Companies and Tools Related Companies Milestone Pharmaceuticals Competitors PMV Pharmaceuticals Competitors Celularity Competitors IGM Biosciences Competitors Maxpro Capital Acquisition Competitors Metagenomi Competitors Assertio Competitors Cabaletta Bio Competitors INmune Bio Competitors Sutro Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CASI) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access